難治性転移性大腸がんにおけるニンテダニブ（BIBF 1120）とプラセボの比較試験（LUME-Colon 1）

基本情報

NCT ID: NCT02149108
ステータス: 完了
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 768
治験依頼者名: Boehringer Ingelheim

概要

The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.

対象疾患

Colorectal Neoplasms

介入

Nintedanib (BIBF 1120)(DRUG)

Placebo(DRUG)

BSC(DRUG)

依頼者（Sponsor）

日本ベーリンガーインゲルハイム株式会社(INDUSTRY)

実施施設 (16)

1199.52.8110 Boehringer Ingelheim Investigational Site

Oita, Yufu, Japan

1199.52.8113 Boehringer Ingelheim Investigational Site

Tokyo , Shinagawa-ku, Japan

1199.52.8111 Boehringer Ingelheim Investigational Site

Tokyo, Koto-ku, Japan

1199.52.8109 Boehringer Ingelheim Investigational Site

Saitama, Kitaadachi-gun, Japan

1199.52.8116 Boehringer Ingelheim Investigational Site

Osaka, Osaka, Japan

1199.52.8101 Boehringer Ingelheim Investigational Site

Chiba, Kashiwa, Japan

1199.52.8105 Boehringer Ingelheim Investigational Site

Chiba, Chiba, Japan

1199.52.8107 Boehringer Ingelheim Investigational Site

Ehime, Matsuyama, Japan

1199.52.8104 Boehringer Ingelheim Investigational Site

Shizuoka, Sunto-gun, Japan

1199.52.8108 Boehringer Ingelheim Investigational Site

Hokkaido, Sapporo, Japan

1199.52.8112 Boehringer Ingelheim Investigational Site

Hyogo, Kobe, Japan

1199.52.8106 Boehringer Ingelheim Investigational Site

Fukuoka, Fukuoka, Japan

1199.52.8103 Boehringer Ingelheim Investigational Site

Osaka, Suita, Japan

1199.52.8115 Boehringer Ingelheim Investigational Site

Hyogo, Amagasaki, Japan

1199.52.8102 Boehringer Ingelheim Investigational Site

Aichi, Nagoya, Japan

1199.52.8114 Boehringer Ingelheim Investigational Site

Ibaraki, Tsukuba, Japan